Generics Bulletin
HBW Insight
In Vivo
Medtech Insight
Pink Sheet
Scrip
Close
Search
Search
In Vivo
Generics Bulletin
HBW Insight
Medtech Insight
Pink Sheet
Scrip
Intarcia Gets Its Hearing: FDA Panel To Weigh Nonapproval Of Diabetes Drug/Device Combo In September
Aug 26 2023
•
By
Sue Sutter
FDA and Intarcia will duke it out at an Endocrinologic and Metabolic Drugs Advisory Committee meeting on 21 September. • Source: Shutterstock
More from US FDA Performance Tracker
More from Regulatory Trackers